Home » REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES
REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES
Thursday morning, Repligen Corp., a biopharmaceutical company, revealed fourth quarter results, reporting a net loss that widened on higher operating expenses and on a 4% decline in revenues.
Trading
Markets
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May